Table 4.
Odds ratios poor vs good/intermediate Overall Treatment Utility (measured at 9 weeks) by frailty score (numeric) and category (for each frailty measure).
| Overall treatment utility Odds ratio (OR) for poor vs good/intermediate OTU, calculated via ordinal logistic regression |
|||
|---|---|---|---|
| Score | Unadjusted OR (CI) | Adjusted a OR (CI) | |
| PS score | numericb | 1.25 (0.99, 1.56) | 1.25 (0.99, 1.58) |
| PS category | 0 | 1 | 1 |
| 1 | 1.38 (0.86, 2.25) | 1.40 (0.86, 2.28) | |
| 2 | 1.65 (0.98, 2.81) | 1.65 (0.97, 2.84) | |
| >2 | 1.83 (0.65, 5.25) | 1.88 (0.64, 5.52) | |
| GO2FS score | numeric | 1.18 (1.06, 1.33) | 1.19 (1.06, 1.33)c |
| GO2FS category | Not frail (0–1) | 1 | 1 |
| Frail (2) | 1.23 (0.74, 2.04) | 1.23 (0.74, 2.06) | |
| Sev frail (≥3) | 1.84 (1.19, 2.85) | 1.85 (1.20, 2.88)c | |
| mCFS score | numeric | 1.14 (1.02, 1.26) | 1.14 (1.02, 1.27) |
| mCFS category | Fit (1–2) | 1 | 1 |
| Pre-frail (3–4) | 1.43 (0.92, 2.22) | 1.45 (0.94, 2.26) | |
| Frail (5+) | 1.72 (1.19, 2.49) | 1.72 (1.19,2.50)c | |
| G8 score | numeric | 0.91 (0.85, 0.97) | 0.91 (0.85–0.97)c |
| G8 category | ≤14 (‘abnormal’) | 1 | 1 |
| >14 (‘normal’) | 0.58 (0.32, 1.00) | 0.57 (0.32, 1.00) | |
| CARG score | numeric | 1.05 (0.99, 1.11) | 1.07 (1.00, 1.13) |
| CARG toxicity risk category | Low (0–5) | 1 | 1 |
| Med (6–9) | 1.43 (0.78, 2.67) | 1.63 (0.84, 3.20) | |
| High (10–19) | 1.75 (0.95, 3.27) | 2.10 (1.07, 4.17)b | |
Statistically significant results in bold. a = adjusted for: age group, sex, histology, presence of metastases, planned use of trastuzumab, dose reduction due to renal or hepatic dysfunction. b = PS >2 was treated as 3 for the purpose of numeric analysis. c = significant after also adjusting for PS.
Abbreviations: OTU = overall treatment utility, PS = Performance Status, GO2FS = GO2 Frailty Score, mCFS = ‘modified’ Clinical Frailty Scale, G8 = Geriatric-8, CARG = Cancer and Aging Research Group.